Trial Profile
A Retrospective, Real-world study to evaluate the safety and efficacy of Safinamide adjunctive therapy for the treatment of motor fluctuations and disabling dyskinesias in patients with idiopathic Parkinson's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 20 Sep 2018 New trial record